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THE ROLE OF DORSAL RAPHE SEROTONINERGIC NEURONS IN SLEEP-
WAKE REGULATION 
REBECCA Y. BROADHURST 
ABSTRACT 
Despite evidence linking the serotoninergic (5-HT) dorsal raphe nucleus (DRN) with the 
regulation of sleep-wake states, lesions of serotoninergic DRN neurons in rats minimally 
alter sleep-wake cycle. The lesion studies are however difficult to interpret given possible 
compensation mechanisms, lack of specificity of the toxins to induce the lesion, and 
incomplete cell loss. The DRN is heterogeneous and contains 5-HT, dopaminergic, 
GABAergic, and glutamatergic neurons. Thus, cell-type specific approaches are needed 
to define the individual contribution of DRN cell populations, including serotoninergic 
DRN neurons, to sleep-wake cycle control. Here we employed a conditional 
chemogenetic approach to selectively and acutely activate serotoninergic DRN neurons 
and analyzed behavioral and electrographic outcomes. Male serotonin reuptake 
transporter (SERT)-Cre driver mice were stereotaxically injected with a Cre-dependent 
adeno-associated viral (AAV) vector expressing an excitatory chemogenetic system 
(AAV-FLEX-hM3Dq-mCherry) into the DRN. The mice were then surgically implanted 
with EEG/EMG recording electrodes to monitor sleep-wake cycle. Injections of the 
hM3Dq ligand, clozapine-N-oxide (CNO; 0.3mg/kg, i.p.) were given at 9:00am (a time of 
high sleep pressure in the nocturnal mouse) and 6:00pm (a time of low sleep pressure in 
the mouse). Changes in behavioral state were determined from EEG/EMG and behavioral 
analysis from video monitoring. Eutopic expression of Cre and hM3Dq in the SERT-Cre 
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mouse was confirmed using standard histological techniques. Administration of CNO at 
9:00am produced a significant increase in NREM sleep during the first post injection 
hour and a significant reduction in latency to sleep. In addition, we report no statistically 
significant reduction in anxiety following acute and selective activation of serotoninergic 
DRN neurons in two anxiety-related behavioral tests, the open field and the elevated plus 
maze. While these results suggest that activation of serotoninergic neurons in the DRN 
may not produce anxiolytic effects, further studies will be required to confirm this. 
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INTRODUCTION 
 
Serotonin 
 Serotonin (5-hydroxytryptamine, 5-HT) was first discovered and isolated in the 
1880s as a blood borne chemical that caused vasoconstriction. This blood borne chemical 
was initially and alternatively called vasoconstrictine, thrombocytin, thrombotonin, 
vasotonin, but was officially termed “serotonin” in 1948. It was subsequently determined 
that serotonin was the same compound as enteramine, a neurotransmitter secreted by 
enterochromaffin cells of the mammalian gut (Hesselink, 1992). Shortly thereafter, 
Twarog and Page (1953) demonstrated high serotonin activity in homogenized brain 
tissue extracts from dogs, rats, and rabbits. From there onwards, 5-HT was determined to 
be an indolamine – which is a monoamine subtype – that functions as a neurotransmitter 
within the Central Nervous System (CNS). 
Serotonin Biosynthesis and Metabolism 
Serotonin is derived from the essential amino acid tryptophan in a two-step 
process. Tryptophan is first hydroxylated to 5-hydroxytryptophan (5-HTP) by tryptophan 
hydroxylase (TPH). 5-HTP is then decarboxylated to form 5-HT by the enzyme L-
aromatic amino acid decarboxylase (Fitzpatrick, 1999). Serotonin is present in various 
organs of the human body such as the skin, gut, lung, kidney, liver, and testis (Azmitia, 
1999) and its primary catabolic pathway is regulated by monoamine oxidase (MAO). 
This enzyme has two forms, MAO-A and MAO-B; however, MAO-A preferentially 
oxidizes 5-HT (Shih et al., 1999). Finally, the serotonin transporter (5-HTT, SERT) 
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located on the presynaptic membrane, controls the reuptake and availability of serotonin 
in the synaptic cleft (Murphy et al., 2004). 
Anatomy of the Serotonin System 
In the 1960s, serotoninergic neurons were first characterized using a 
formaldehyde-induced fluorescence technique. Histological analysis revealed that the 
majority of 5-HT cell bodies are located in the midline brainstem, including within the 
dorsal raphe (DR). These 5-HT brainstem nuclei, alternatively called the raphe nuclei, 
were subdivided into nine different cell groups, termed B1-B9 in the caudal to rostral axis 
(Table 1) (Dahlström & Fuxe, 1964). These cell groups were then further subdivided into 
two major groups, rostral (B5-B9) and caudal (B1-B3), distinct from each other by 
developmental differences and migratory pattern. The first serotoninergic cells are 
formed in the rostral group at 12 days’ gestation in the rat, while the first serotoninergic 
cells in the caudal group form two days later (Jacobs & Azmitia, 1992). 
Table 1. Anatomical Designation of Serotoninergic Cell Groups in the Raphe Nuclei and Brainstem 
Reticular Formation and the Corresponding Classification into the B Groups, According to 
Dahlström & Fuxe (Table taken from Törk, 1990). 
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The rostral group contains the caudal linear nucleus (CLi), the dorsal raphe 
nucleus (DRN), and the median raphe nucleus (MnR) (Dahlström & Fuxe, 1964; Törk, 
1990). Notably, the dorsal raphe nucleus (DRN), represented by the B7 and B6 groups, 
contains the largest population of serotoninergic neurons in the brain (Jacobs & Azmitia, 
1992). The caudal group contains the raphe magnus nucleus (RMg), the raphe obscurus 
(ROb), and the raphe pallidus nucleus (RPa) (Table 1) (Dahlström & Fuxe, 1964; Törk, 
1990). In addition, there are also serotoninergic neurons in the lateral medullary reticular 
formation, continued from the lateral wings of the RMg (Steinbusch, 1981). 
 
Figure 1. Representative drawing of serotoninergic cell groups in the raphe nuclei and reticular 
formation, as they would appear on a sagittal projection through the cat brainstem. Rostral (left) and 
caudal (right) divisions of the serotoninergic system seem continuous, but are separate. 3: oculomotor 
nucleus, 12: hypoglossal nucleus, 4V: 4th ventricle, Aq: cerebral aqueduct, Cb: cerebellum, IP: 
interpeduncular nucleus, mlf: medial longitudinal fasciculus, PAG: periaqueductal grey matter, Pn: pontine 
nuclei, py: pyramid, RtTg: reticular tegmental nucleus of pons, xpy: pyramidal decussation, xscp: 
decussation of superior cerebellar peduncles. (figure taken from Törk, 1990). 
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Visualization of the serotoninergic system has been achieved using 
immunocytochemical detection of TPH (Pickel et al., 1977), 5-HT (Steinbusch, 1981), or 
SERT (Nielsen et al., 2006) and has revealed dense and widespread projections across the 
neuraxis of adult rat brain. While both rostral and caudal groups of the DR have 
projections to the brainstem, projections of the rostral group predominantly target the 
forebrain whereas projections of the caudal group predominantly target the spinal cord 
(Hornung, 2010). 
Efferent projection to the forebrain from the rostral group ascend via parallel 
dorsal and ventral pathways. The dorsal pathway projects to the medial forebrain bundle 
in addition to connecting to the ventral pathway; however the ventral pathway mainly 
projects to the basal forebrain (BF) and medial cortex (Hornung, 2010). Additionally, the 
rostral DRN projects to the cerebral cortex, neostriatum, amygdala, and the substantia 
nigra (Azmitia & Segal, 1978), whereas a more caudal division of the DR projects to the 
hippocampus and locus coeruleus (LC) (Imai et al., 1986). Finally, the rostral DR also 
projects to the thalamus, prefrontal cortex, nucleus accumbens, lateral geniculate nucleus, 
and trigeminal nucleus (Hornung, 2010). 
As indicated, the caudal group’s efferent projections primarily target the caudal 
brainstem and the spinal cord (Skagerberg & Björklund, 1985). The ROb and the RPa 
contain major serotoninergic input to brainstem somatic motor nuclei, which include the 
motor trigeminal nucleus and the facial nucleus (Li et al., 1993). Within those that project 
to the spinal cord, there is a dorsal division containing axons with small varicosities and a 
ventral division with large varicosities (Ridet et al., 1993). Finally, caudal serotoninergic 
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neurons also innervate the phrenic nucleus, lumbar motor neurons, autonomic motor 
neurons of the sympathetic and parasympathetic systems (Hornung, 2010). 
 
Sleep-Wake Circuitry and Neurotransmitters 
 Sleep is a behavioral state expressed by all mammals and is characterized by a 
reduction of voluntary motor activity, decreased response to stimulation, and stereotypic 
posture. During sleep, there are repeated cycles of two distinct sleep stages, rapid eye 
movement (REM) and non-REM (NREM). These stages are characterized by distinct 
patterns of activity in the electroencephalogram (EEG) and electromyogram (EMG) 
recordings (Weber, 2017). While wakefulness shows desynchronized, high frequency, 
low amplitude waves (beta waves, 30 Hz) in the cortical EEG, NREM sleep EEG waves 
are slower in frequency and higher in amplitude (delta waves, 1-4 Hz). During REM 
sleep, cortical EEG waves resemble the cortical EEG activity of wakefulness with high 
frequency and low amplitude waves, but unlike wakefulness, skeletal muscles are 
paralyzed and, as its name implies, rapid eye movements occur (Fuller et al., 2006). 
 While the neural basis of sleep remains incompletely understood, models of brain 
circuitry controlling sleep and wake continue to be refined and developed. Early models, 
such as the “ascending reticular activating system” theory, proposed a wake promoting 
brainstem influence as the origin of an activating brainstem-thalamus-cortical pathway. 
This pathway has two components, one originating from cholinergic (Ach) cell groups of 
the upper brainstem, the pedunculopontine (PPT) and laterodorsal tegmental (LDT) 
nuclei, which ascended to the thalamus to activate thalamic relay nuclei crucial for 
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transmission to the cortex. Additional arousal influence was thought to derive from 
monoaminergic cell groups, including histaminergic neurons in the tuberomammillary 
nucleus (TMN), dopaminergic neurons in the ventral periaqueductal grey matter (vPAG), 
serotoninergic neurons in the dorsal and median raphe, and noradrenergic cells in the LC, 
which bypassed the thalamus and activated neurons in the lateral hypothalamus and basal 
forebrain, as well as the cerebral cortex (Saper et al., 2005). With respect to sleep-
promoting circuitry, early experiments identified a sleep promoting influence from the 
preoptic hypothalamus (Nauta, 1946), including the ventrolateral preoptic (VLPO) and 
median preoptic nuclei (MnPO). The VLPO and MnPO contain Gamma-Aminobutyric 
acid (GABA) neurons have been hypothesized to inhibit arousal during sleep (Sherin et 
al., 1998). 
Given the arrangement of the brain’s sleep-wake apparent reciprocal arrangement, 
in which arousal circuits inhibit sleep circuits to produce wake, and sleep circuits inhibit 
wake circuits to produce sleep, it was hypothesized that the brain’s sleep-wake circuitry 
may function analogously to an electronic “flip-flop” switch (Figure 2). In this flip-flop 
arrangement, the activity of one “side” (e.g., wake circuitry) can shut down the inhibition 
from the other side, disinhibiting its own action. This self-reinforcing inhibition results in 
a lack of transitional states to ensure stability of each discrete state and allow for fast 
switching. 
A lack of transitional states can also lead to unpredictable and inappropriate state 
switching, especially when one side might be weaker and less able to inhibit the other 
side (Saper et al., 2005). For example, rats with lesions in the VLPO tend to fall asleep 
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about twice as much compared to normal animals, wake up more often, but only sleep 
one-quarter as long per bout (Lu et al., 2000). This was common and similar to 
descriptions of sleep in elderly patients, who report sleep fragmentation and more 
napping during the day, most likely from a weakened VLPO from aging (Fuller et al., 
2006). 
The sleep-wake flip-flop model also included input from the lateral hypothalamic 
orexin neurons. These neurons are active during wakefulness and motor activity and they 
have projections that ascend to the cerebral cortex and descend to the monoaminergic and 
cholinergic cell groups of the arousal systems (Peyron et al., 1998). Mice that lack orexin, 
i.e., orexin knock out mice, have a sleep phenotype similar to human and animal 
narcolepsy in which there is cataplectic episodes (complete loss of muscle tone while 
remaining consciousness) and increased sleep fragmentation (Chemelli et al., 1999). 
However, while there are mutual projections between the VLPO and orexin neurons, 
there are no orexin receptors in the VLPO (Marcus et al., 2001). Therefore, orexin 
neurons were thought to have more of a stabilizing effect on the flip-flop switch through 
excitation of the ‘wake’ side of the switch (e.g. TMN, DR, LC) which would serve to 
prevent unwanted transitions into sleep (Figure 2) (Saper et al., 2005). 
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Figure 2. A schematic diagram of the flip-flop switch model. During wakefulness, A) the monoaminergic 
nuclei (red) inhibit the ventrolateral preoptic nucleus (VLPO; purple), stopping the inhibition of the 
monoaminergic cells and orexin neurons (green). Since the VLPO has no orexin receptors, the orexin 
neurons serve to reinforce monoaminergic tone. During sleep, B) the firing of the VLPO neurons inhibits 
the monoaminergic nuclei, stopping their own inhibition and allows for the VLPO to inhibit orexin neurons 
that usually activate monoaminergic cell groups (figure from Saper et al., 2005). 
 
Despite the elegance and intuitive appeal of these earlier models, i.e., cholinergic 
and monoaminergic brain arousal systems, several more recent experiments have 
revealed serious shortcomings (Fuller et al., 2011). For example, it has been shown that 
lesioning individual components of putative wake promoting cell groups, either 
separately or together, has had little effect on the daily amount of sleep-wake on rodents 
(Gerashchenko et al., 2004; Lu et al., 2006; Gompf et al., 2010; Fuller et al., 2011; 
Petrovic et al., 2013). Therefore, a recent paradigm shift in sleep-wake circuitry has 
emerged. Monoaminergic, cholinergic, and peptidergic neurons in the brainstem and 
hypothalamus, which were originally thought to play a prominent role in earlier sleep-
wake models, are now thought to play a more modulatory role (Saper & Fuller, 2017). 
While earlier models point to the thalamus as necessary for generating cortical 
arousal and wakefulness, previous studies have reported the thalamus is not necessary to 
maintain an aroused cortical state in rats (Buzsaki et al., 1988). Additionally, extensive 
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lesioning of the thalamus had little effect on EEG or behavioral measures of wakefulness 
or on cortical c-Fos expression (Fuller et al., 2011). Instead, there is much more evidence 
supporting a BF arousal system. Specifically, large and combined lesions of all three cell 
types present in the BF, which includes cholinergic, GABAergic, and glutamatergic 
groups, caused a permanent slow wave state along with behavioral unresponsiveness 
(Fuller et al., 2011). Additionally, acute and selective activation of GABAergic neurons 
in the BF potently drives waking (Anaclet et al., 2015). Furthermore, optogenetic 
activation of BF parvalbumin-containing GABA neurons produced high-frequency 
gamma activity in cortical EEG, which is associated with wakefulness and higher level 
cortical function (Kim et al., 2015). 
In addition, glutamatergic neurons of the PB and PPT, both of which send input to 
the BF, have also shown to be potently wake promoting when activated. Large lesions of 
the PB also produces low frequency EEG, behavioral unresponsiveness, and a reduction 
of cortical c-Fos positive neurons during gentle handling (Fuller et al., 2011). 
Chemogenetically activating glutamatergic neurons in the PPT, which invariably 
included the rostral pole of the PB, induced a prolonged cortical EEG and behavioral 
wakefulness, while inhibition reduced wakefulness and increased NREM sleep. However 
the same selective activation of intermingled cholinergic and GABAergic neurons in the 
PPT caused no major effects on sleep-wake (Kroeger et al., 2017). Finally, chemogenetic 
activation of glutamatergic neurons in the supramammillary (SuM) region, which 
extensively innervates the cerebral cortex, BF, and hippocampus, has also been shown to 
produce sustained EEG and behavioral arousal (Pedersen et al., 2017). 
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Other experiments have also suggested a role for two peptidergic neuronal 
systems, orexin and melanin-concentrating hormone (MCH), located in the lateral 
hypothalamus as playing an important role in arousal. For example, orexin neurons are 
most active during wakefulness (Mileykovskiy et al., 2005) and LH MCH neurons are 
most active during REM sleep (Verret et al., 2003). Of note, and more recently, a 
population of GABAergic neurons within the ventral LH was shown to produce sustained 
wakefulness in mice when chemogenetically activated (Venner et al., 2016). A similar (or 
possibly the same; this has yet to be determined) population of GABAergic neurons from 
the dorsal LH were also shown to cause rapid arousal from NREM sleep when 
optogenetically activated (Herrera et al., 2016). 
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Figure 3. Diagram summarizing the fast neurotransmitter systems that appear to promote 
wakefulness. Monoaminergic, cholinergic, peptidergic neurons in brainstem and hypothalamus (brown). 
Lesions at these sites have little effect on sleep-wake amounts. The backbone of the arousal system in this 
model (red) is the glutamatergic input from the parabrachial nucleus (PB) and the pedunculopontine 
tegmental nucleus (PPT) to the basal forebrain (BF), and the GABAergic and cholinergic neurons in the BF 
that diffusely innervate the cerebral cortex. Lesions at these sites cause complete loss of consciousness. 
Finally, two populations of GABAergic neurons in the lateral hypothalamus (LH) (purple) have recently 
been proposed to promote wakefulness by inhibiting sleep promoting neurons in thalamus and preoptic area 
(figure taken from Saper & Fuller, 2017). 
 
As a potent counterpoint to the brain’s arousal system, the preoptic VLPO and 
MnPO contain sleep-promoting GABAergic and galanin-containing neurons. In addition, 
a delimited node of sleep-promoting GABAergic neurons in the medullary parafacial 
zone (PZ) was recently uncovered. Chemogenetic activation of PZ GABAergic neurons 
was shown to rapidly initiate slow wave sleep, regardless of the time of day. 
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Additionally, PZ GABA neurons were shown to project to and inhibit wake promoting 
PB neurons, which then project to the BF (Figure 4) (Anaclet et al., 2014). All together, 
these recent studies suggest that the ‘backbone’ of the sleep-wake circuit system 
comprises the fast neurotransmitters, GABA and glutamate, with the monoaminergic, 
cholinergic, and peptidergic neurons in the brainstem and thalamus playing a more 
regulatory role (Saper & Fuller, 2017). 
 
Figure 4. Diagram summarizing the fast neurotransmitter systems that contribute to sleep. Sleep 
promoting systems (purple) include the ventrolateral preoptic (VLPO) and median preoptic (MnPO) 
GABAergic neurons that send axons to most components of the arousal system (shown in red, yellow, and 
green) and are thought to work together to inhibit them. Parafacial zone (PFZ) GABAergic neurons in the 
medulla promote sleep by inhibiting the parabrachial glutamatergic arousal neurons (figure taken from 
Saper & Fuller, 2017). 
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Role of Serotonin in Sleep-Wake Cycle 
An interrelationship between serotonin and sleep regulation went unrecognized 
until 1955, when the administration of reserpine, which inhibits the reuptake of 
norepinephrine and results in the decrease of 5-HT, was shown to produce a sedated or 
sleep-like state (Brodie et al., 1955). A decade later, reserpine was also shown to initiate 
REM sleep during wake and sleep in cats (Delorme et al., 1965). Monoamine oxidase 
inhibitors, which increase the level of serotonin, had the opposite effect and could abolish 
REM sleep in the cat for days or weeks (Jouvet et al., 1965). Later, the depletion of 
serotonin with p-chlorophenylalanine (PCPA), a tryptophan hydroxylase inhibitor, also 
was shown to produce a suppression of sleep or persistent insomnia in cats (Delorme et 
al., 1966), a more convincing link between serotonin and sleep emerged when an 
intraventricular injection of L-5-hydroxytryptamine (L-5-HTP), the immediate precursor 
to 5-HT, which by-passes the inhibition of the synthesis by PCPA, reversed the insomnia 
that occurred after administration of PCPA (Koella, 1969). Therefore, indications from 
these early pharmacologic studies pointed to 5-HT as a “sleep-promoting” 
neurotransmitter, resulting in the monoaminergic theory of sleep and waking. 
The monoaminergic theory of sleep-wake hypothesized that DR neurons were 
responsible for slow wave sleep (SWS) through the release and binding of serotonin to 
postsynaptic receptors that, in turn, produced sleep posture, decrease of muscle tone, and 
EEG synchronization. This theory also postulated that noradrenaline and dopamine 
groups in the LC and substantia nigra, respectively, worked together with the cholinergic 
ascending systems to produce wakefulness (Jouvet, 1972). 
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However, in contradiction to the emerging story, electrical activity of 5-HT 
perikarya (McGinty & Harper, 1976) and release of 5-HT (Cespuglio et al., 1984) were 
shown to decrease during sleep and increase during wake in cats and rats, respectively, 
leaving investigators puzzled. It was eventually confirmed by microdialysis that naturally 
behaving cats showed high extracellular 5-HT concentrations with wake behavioral states 
and low extracellular 5-HT concentrations with SWS and REM states (Portas & 
McCarley, 1994). No longer considered a sleep neurotransmitter, serotonin’s role in 
sleep-wake had to be revised. To complicate the story yet again, injections of 5,7-
dihydroxytryptamine into the vPAG of rats caused marked loss of 5-HT neurons in the 
DR, but surprisingly had no significant effects on sleep (Lu et al., 2006) implying that 5-
HT plays no role in the regulation of arousal state at all. 
Another interesting aspect of serotonin’s complicated history with sleep includes 
the effects of Selective Serotonin Reuptake Inhibitors (SSRIs). SSRIs are a class of drugs 
commonly used as anti-depressants, which act to inhibit reuptake of serotonin by the 
SERT and consequently increase the amount of serotonin. In humans, SSRIs, such as 
fluoxetine and monoamine-oxidase inhibitors (MAOI, e.g., phenelzine), that result in the 
increase of circulating 5-HT, markedly suppress REM sleep (Palagini et al., 2013). In 
rats, the SSRI cericlamine also consistently reduces REM sleep, however its effects have 
been mixed: following an acute and low dose, rats had decreased REM and increased 
SWS, whereas chronic administration led to tolerance and a rebound of REM sleep on the 
first day of withdrawal (Maudhuit et al., 1994). Therefore, the role of 5-HT in arousal 
regulation remains to be resolved. 
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SSRIs and Behavior 
SSRIs, which act to increase 5-HT, are frequently prescribed for the treatment of 
depression and anxiety disorders. While the 5-HT deficiency theory of depression is 
based on SSRIs’ ability to alleviate symptoms, most agree that the 5-HT deficiency is not 
the root cause and is a broad overgeneralization (Jacobsen et al., 2012). However, the 
DRN, a major source of 5-HT neurons, has strong projections to many areas that have 
been linked to reward behaviors such as the midbrain ventral tegmental area (VTA), 
nucleus accumbens (NAc) shell, ventral pallidum, hypothalamus, anterior cingulate 
cortex, and orbitofrontal cortex (Jacobs & Azmitia, 1992; Wise & Rompre, 1989). Direct 
optogenetic stimulation of DRN neurons, through the release of glutamate and 5-HT, 
have been shown to bias mice towards reward-associated behaviors (Liu et al., 2014). 
The DRN also has strong connections to limbic forebrain structures, such as the 
prefrontal cortex, cingulate cortex, entorhinal cortex, hippocampus, NAc, ventral 
pallidum, amygdala, and anterior hypothalamus, areas often associated with mood and 
emotion (Iversen et al., 2000). Additionally, 5-HT transmission to the limbic system is 
described as paracrine, which requires the neurotransmitter to diffuse and travel to 
distantly-located receptors (Descarries & Mechawar, 2000). These specific characteristics 
of the DRN support a neuromodulatory role for 5-HT, especially for anxiety-related 
circuits. In addition, acute and chronic activation of serotoninergic DRN neurons also 
causes an antidepressant effect, however only acute activation of serotoninergic DRN 
neurons can induce anxiolytic-like behaviors (Urban et al., 2016). 
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Objective 
The general objective of this thesis was to examine the specific role of 
serotoninergic DRN neurons in sleep and wakefulness in the mouse. While much of the 
DRN is populated by serotoninergic neurons, the cellular DRN is a remarkably 
heterogeneous structure, containing numerous other non-5-HT neuronal cell-types, 
including: GABAergic, glutamatergic, and dopaminergic neurons. GABAergic neurons 
are distinct from 5-HT with limited co-localization, while glutamatergic neurons are 
intermixed and co-localized with 5-HT (Calizo et al., 2011). DA neurons, while less 
common (~1000 cells), are also present (Descarries et al., 1986). Therefore, cell-type 
specific approaches will be required and used to selectively enhance 5-HT 
neurotransmission to determine the precise role of the serotoninergic DRN in sleep-wake 
regulation. 
 We employed a chemogenetic strategy to selectively activate serotonergic 
neurons in the DRN. Chemogenetics is a cell-type specific technique in which 
macromolecules can be engineered to interact with otherwise pharmacologically inert 
small molecules. The most widely used chemogenetic strategy is the Designer Receptors 
Exclusively Activated by Designer Drugs (DREADDs) system, which utilizes a mutated 
human muscarinic GPCR. DREADDs have a low affinity for endogenous ligands and 
show little constitutive activity, but can be activated by synthetic ligands like clozapine-
n-oxide (CNO) (Armbruster et al., 2007). CNO activation of the modified muscarinic M3 
DREADD receptor, coupled to excitatory or Gq signaling, results in the firing of neurons 
(Alexander et al., 2009). 
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While numerous prior studies have investigated the role of serotonin in sleep-
wake and promoted serotonin’s supposed role in arousal, the precise and selective 
modulation of this population by chemogenetics has not yet been achieved. Therefore, to 
investigate the role of serotoninergic DRN neurons in sleep-wake, SERT-Cre transgenic 
mice that express Cre-recombinase under the control of the SERT promoter, will be 
stereotaxically injected in the DRN with an Cre-dependent adeno-associated virus (AAV) 
carrying the transcript for hM3Dq. The AAV will only express the hM3Dq receptor when 
Cre-recombinase is present in the neuron, allowing us to selectively target the 
subpopulation of serotoninergic neurons within the DRN. After injection of the hM3Dq 
activating ligand, CNO, sleep-wake will be recorded by EEG screws and EMG leads, and 
will be scored as wake, NREM, or REM. 
Previous studies have connected serotonin to anxiety-related behaviors, however 
there are conflicting reports of anxiogenic (Teissier et al., 2015) vs. anxiolytic behaviors 
(Urban et al., 2016) after chemogenetically activating serotoninergic neurons in the DRN, 
which most likely reflects differences in transgenic mouse lines and methodologies 
employed. Therefore, to fully characterize the behavioral effects of specifically activating 
serotoninergic DRN neurons, the same SERT-Cre mice injected with hM3Dq in the DRN 
will also be tested with a battery of behavioral tests, including an open field test and an 
elevated plus maze to measure anxiety-related behavior. 
Specific Aims and Objectives 
1. Validate the 5-HT expression pattern in the SERT-Cre mouse  
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2. Test the hypothesis that acute and selective activation of serotoninergic neurons in 
the DRN will increase wakefulness and decrease sleep in the mouse. 
3. Test the hypothesis that acute and selective activation of serotoninergic neurons in 
the DRN will induce anxiolytic behaviors in the mouse. 
4. Inform the current circuit-based model of sleep-wake. 
	19 
METHODS 
 
Animals 
 Adult male SERT-Cre mice and their wildtype littermates (8-12 weeks) (n=8) 
were used in this study. Transgenic SERT-Cre mice (RRID: MMRRC_017260-UCD) 
were generated with a modified bacterial artificial chromosome (BAC)-Cre construct 
encoding the serotonin transporter gene (Slc6a4, SERT) (Gong et al., 2007). Mice were 
bred and housed in our animal facility, were genotyped before and after experiments, 
subjected to a 12-hour light/dark cycle, and had access to food and water ad libitum. All 
procedures were approved by the Institutional Animal Care and Use Committee of Beth 
Israel Deaconess Medical Center. 
 
Surgery 
 Mice were anesthetized with ketamine/xylazine and placed into a stereotaxic 
apparatus. To selectively express hM3Dq in serotoninergic (SERT) neurons of the DRN, 
midline injections of an adeno-associated viral (AAV) vector expressing hM3Dq-
mCherry receptor (hSyn-DIO- hM3D-mCherry- AAV10)	were placed into the DRN (AP 
= -4.4 mm; ML= 0.0 mm; DV= -2.25 mm) using a compressed air delivery system. The 
scalp wound was closed with VetbondTM, a nontoxic tissue adhesive. Mice recovered for 
two weeks post brain injection and then underwent EEG/EMG headstage surgery. 4 EEG 
screw electrodes (Pinnacle, Lawrence, KS) and 2 flexible EMG wire electrodes (Plastics 
One, Roanoke, VA) were soldered onto a 6-pin connector (Mill-max, Oyster Bay, NY) 
and then implanted and secured with dental cement (Figure 5). Before surgery, all mice 
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received Meloxicam SR, an analgesic, and recovered for two weeks post headstage 
surgery. 
	
Figure 5. Representative drawing of a mouse skull with dorsal placement of headstage. 4 EEG screws 
(open circles) equidistantly placed from Bregma (x) and 2 EMG leads (black filled circles) directed towards 
the mouse’s body. 
 
Sleep-Wake Monitoring 
 Following a four-week post brain injection period, the mice were housed 
individually in transparent barrels in an insulated sound-proofed recording chamber 
maintained at an ambient temperature of 22 ± 1°C and on a 12-hour light/dark cycle 
(lights-on at 6am, Zeitgeber time: ZT0) with food and water available ad libitum. Mice 
were habituated to the recording cable for 4 days before starting polysomnographic 
recording. During this habituation period, mice were picked up and handled once a day. 
Mice were recorded for a 24-hour baseline period and then injected with CNO (RTI 
International; Research Triangle Park, NC, 0.3 mg/kg in saline, i.p.) at 9am (ZT3, light 
period, time of high sleeping drive) and 6pm (ZT12, lights-off, time of high waking 
drive). After each CNO injection, there was a 48-hour washout period. As an injection 
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control, mice were also injected with saline at 9am and 6pm following a within-subject 
design (Figure 6).	
 
Figure 6. Experimental design for sleep-wake monitoring. All SERT-Cre mice injected with AAV-DIO-
M3 (n=8) underwent sleep-wake monitoring in individual barrels for a total of 11 days. Habituation took 
place during the first four days, during which mice were handled once a day. The first day was a 24-hour 
baseline recording, without any handling. Mice were then injected, on separate days, at 9am and 6pm with 
saline (i.p) and CNO (0.3 mg/kg, i.p.) and their sleep-wake was recorded for 24-hours (saline) or 48-hours 
(CNO). Every CNO injection had a wash-out period of 48-hours to ensure no CNO was present in their 
system. 
 
Sleep Scoring and Analysis 
 Cortical EEG (ipsilateral frontoparietal) and EMG signals were amplified and 
digitalized with a resolution of 500 Hz Vital Recorder (Kissei, Japan). Polysomnographic 
records were visually scored using SleepSign for Animal (Kissei, Japan) in 10 second 
epochs for wakefulness (W), rapid eye movement (REM), and non-REM (NREM) sleep. 
The percentage of time spent in W, REM, and NREM sleep were calculated for each 
mouse. 
 
Behavioral Test Battery 
 All behavioral tests took place during the day, consistently between 9am-1pm. 
Mice were brought into the test room and habituated for at least 60 minutes before the 
start of the experiment. All mice were first tested in the open field and then the elevated 
plus maze. Mice were tested in a randomized crossover design (Figure 7). 
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Figure 7. Experimental design for behavioral battery of anxiety-related tests. All mice (n=8) were 
habituated in the test room for 1 hour prior to behavioral tests. All mice were first challenged in the open 
field test for 10 minutes on two separate days, at least 48-hours apart, with either CNO (0.3 mg/kg, i.p.) or 
saline (i.p.) 10 minutes before the test in a randomized crossover design. After another 48-hours, mice were 
then challenged in the elevated plus maze for 10 minutes on two separate days, at least 48-hours apart, also 
with either CNO (0.3 mg/kg, i.p.) or saline (i.p.) 10 minutes before the test in a randomized crossover 
design. 
 
Open Field Test 
10 minutes after injection of either CNO (0.3 mg/kg in saline, i.p.) or saline (i.p.), 
mice were placed into the center of a large square chamber (48.5 x 48.5 x 30cm) made of 
grey KOMATEX and were allowed to freely explore the chamber for 10 minutes while 
their movement was tracked and recorded by EthoVision 8.5 tracking software (Noldus, 
Leesberg, VA). The center was defined as a square comprised of 50% of the total area of 
the chamber. Time spent in the surround vs. the center was the primary measure of 
anxiety behavior as mice typically spend a significantly greater amount of time exploring 
the periphery rather than the unprotected center area. Once the test was completed, mice 
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were returned to their home cage and the chamber was cleaned with Clidox (Pharmacal 
Research Laboratories, Waterbury, CT) between each trial. 
Elevated Plus Maze 
 Mice were brought into the test room and habituated for at least 60 minutes. 10 
minutes after injection of either CNO (0.3 mg/kg in saline, i.p.) or saline (i.p.), mice were 
placed at the center of the elevated plus maze. The maze apparatus was made from white 
and Plexiglas and consists of two opposing open arms (60.5 x 7 cm) and two opposing 
closed arms (60.5 x 7 x 12 cm), arranged in a plus configuration and elevated 75 cm. 
During the 10 minutes of free exploration, their movements are tracked by EthoVision 
8.5 software tracking (Noldus, Leesberg, VA). The primary measure of anxiety behaviors 
was the time spent in the closed arms vs. the open arms as mice tend to avoid the open 
areas and favor darker and more enclosed areas. After the trial, mice were returned to 
their home cage and the maze was cleaned with Clidox (Pharmacal Research 
Laboratories, Waterbury, CT) between each trial. 
 
Immunohistochemistry 
 Animals were injected with either CNO (0.3 mg/kg in saline, i.p.) or saline (i.p.) 
at 9am and were killed 90 minutes later by deep anesthesia with 200 mg/kg chloral 
hydrate, followed by immediate transcardial perfusion with 20 mL saline and then 100 
mL of neutral phosphate buffered formalin (4%, Fischer Scientific). Brains were removed 
and incubated in 20% sucrose at 4˚C until they sank, then sectioned at 40 µm on a 
freezing microtome in three series. As previously described in Venner et al., 2016, brain 
sections were washed in phosphate buffered saline (PBS), and incubated in primary 
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antiserum (dsRed rabbit polyclonal antibody (1:10K)	(Clontech; catalog number 632496), 
and/or c-Fos rabbit polyclonal antibody (1:15K)	(Oncogene Sciences; catalog number 
4188), or 5-HT goat polyclonal antibody (1:5K)	(Immunostar; catalog number 20079) 
diluted in PBS containing 0.3% Triton X-100 (PBST) and 0.2% sodium azide overnight 
at room temperature. To detect primary antibodies, sections were washed in PBS and 
incubated in biotinylated secondary antiserum (against appropriate species IgG, 1:1000, 
Jackson ImmunoResearch) in PBST for two hours, washed in PBS and incubated in ABC 
reagents (Vectastain, Vector Laboratories, Burlingame, CA) in PBST for 1 hour. Sections 
were washed again and then reacted in a solution of 0.02% 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Sigma) and 0.009% hydrogen peroxide. The sections were 
stained brown with DAB or black (c-Fos) by DAB plus 0.005% cobalt chloride and 
0.01% nickel ammonium sulfate. For double staining of protein markers using antibodies 
raised in the same species, the same sections were processed twice in serial fashion as 
follows: immunohistochemistry against cFos was processed and visualized with DAB 
and nickel-cobalt to visualize a black byproduct localized to the nucleus. After the first 
reaction was complete, immunochemistry against dsRed was processed and visualized 
with DAB without nickel-cobalt to produce a brown byproduct throughout the cytoplasm 
of transduced cells. For fluorescent detection of primary antibodies, sections were 
washed 3 times in PBS and incubated in fluorescent secondary antiserum for 2 hours 
(against appropriate species IgG, 1:500, Jackson ImmunoResearch). Sections were then 
washed twice in PBS and then mounted on positive charged slides (Denville Scientific, 
Inc.). 
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Statistical Analysis 
 All data are presented as the mean ± standard error of mean (S.E.M). Statistical 
analysis was performed using Prism v6 (GraphPad Software, San Diego, CA, USA). 
Differences with P < 0.05 were considered significant. When examining time-course, 
two-way ANOVA for repeated measures was used for analysis, with Sidak post-hoc test. 
Latency to sleep, number of bouts, and bout latency were compared by paired t-test. The 
differences following CNO and saline injections in mice who had hM3Dq expression or 
no expression were compared by two-way ANOVA.  
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RESULTS 
 
Validation of SERT-Cre mouse 
 To genetically isolate serotoninergic neurons, a transgenic mouse expressing the 
enzyme Cre-recombinase under the control of the SERT promoter (SERT-Cre) was used. 
In the DRN, SERT should be expressed exclusively in serotoninergic neurons. To 
validate the selectivity of the SERT-Cre transgenic mouse, we used SERT-Cre, lox-
GFPL10 mice (Krashes et al., 2014). In the DRN of these mice, neurons expressing the 
L10-green fluorescent protein (GFP) reporter colocalized with serotoninergic neurons 
identified with an antibody to 5-HT, validating that Cre was expressed eutopically in the 
SERT-Cre mouse (Figure 8). 
 
Figure 8. Validation of the SERT-Cre mouse with immunolabeling. Florescent images of SERT-Cre-
GFP+ (green) neurons show colocalization with 5-HT+ (red) neurons in the DRN, scale bars: 200µm. 
 
Conditional activation of serotoninergic DRN neurons reduces wakefulness and 
elevates NREM sleep in the first hour after 9:00am injection of CNO 
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To investigate the role of serotoninergic DRN neurons in regulating arousal, we 
used a conditional chemogenetic approach to reversibly activate serotoninergic DRN 
neurons during polysomnography recordings. Stereotaxic injections of an AAV encoding 
the excitatory DREADD, hSyn-FLEXhM3Dq-mCherry-AAV10 (AAV-hM3Dq), into the 
DRN of SERT-Cre mice ensured only serotoninergic DRN cells would be transfected 
with hM3Dq (Figure 9). 
	
Figure 9. Schema of hM3Dq-mCherry construct and viral targeting to the DRN of SERT-Cre mice. 	
Following administration of intraperitoneal (i.p.) injections of the hM3Dq ligand 
(CNO) and vehicle (saline), mice were monitored for sleep-wake by polysomnography. 
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Their arousal state was scored based upon both EEG and electromyogram EMG signals, 
as well as visual confirmation via video recordings. Injections of CNO (0.3 mg/kg, i.p.) at 
9:00am, a time of peak sleep drive in the mouse, reduced the time spent awake 
(p=0.0006) and promoted NREM sleep during the first hour post injection (p=0.0001) 
compared to saline (i.p.) (Figure 10A-C). 
	
Figure 10. Conditional activation of serotoninergic DRN neurons on sleep-wake. Percentage of 6-hour 
wake (A), NREM sleep (B), and REM sleep (C) following 9am injection of CNO or saline within the same 
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mouse (n=6). Percentage of 6-hour wake (D), NREM sleep (E), and REM sleep (F) after 6:00pm injection 
(n=6). Mean + SEM, repeated measures two-way ANOVA, followed by Sidak post test. *** p < 0.001. 
 
To further examine why NREM sleep was elevated following activation of the 
DREADD, we compared the latency to the first episode of NREM between CNO and 
saline injection conditions. Mice injected with CNO at 9am had a significant (p=0.0107) 
reduction in latency to sleep compared to saline (Figure 11A). There was a small increase 
in bout count and bout length, albeit not statistically significant (p=0.3098; p=0.1088), in 
CNO injected animals compared to saline (Figure 11B-C). The administration of CNO at 
6pm, a time of high waking drive in the mouse, did not increase wake (time factor F [5, 
25]=0.4879, p=0.7820; injection factor F[1,5]=0.8966, p=0.3872), decrease NREM (time 
factor F [5, 25]=0.4973, p=0.7752; injection factor F[1,5]=1.036, p=0.3555) or change 
percentage of time spent in REM sleep (time factor F [5, 25] =0.7228, p=0.6126; 
injection factor F[1,5]=4.139, p=0.0976) with respect to saline (Figure 10D-F). 
Figure 11. First hour post-9am injection of CNO or saline. Mice in the first hour post-9am injection of 
CNO or saline (n=6) in terms of: A) latency to sleep, B) number of NREM bouts, C) mean length of 
NREM bouts. Mean + SEM, paired t-test. * p < 0.05. 	
To confirm the injection of the hM3Dq ligand CNO selectively activated DRN 
neurons transfected with hM3Dq in vivo, mice were injected with either CNO or saline 
and perfused after 90 minutes. Following sectioning, slices containing the DRN were 
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stained for the immediate early gene c-Fos, which is upregulated by neuronal activity. 
Colocalization of hM3Dq-mCherry and c-Fos was observed in CNO injected animals 
compared to saline injected animals, indicating that the administration of CNO 
selectively activated serotoninergic DRN neurons transfected with hM3Dq (Figure 12). 
Figure 12. CNO activates neurons transduced with hM3Dq-mCherry. Double immunolabeling against 
mCherry (brown) and c-Fos (black) in SERT-Cre cell bodies after injection of saline (left) or CNO (right) 
in SERT-Cre mice at 9 a.m., 90 min prior to sacrifice. Colocalization of mCherry and c-Fos (black open 
arrows) was present in the CNO injected mice, while only mCherry+ cells (white arrows) were present in 
saline injected mice. Scale bars: 100µm. 
 
 To more precisely define the anatomical region of serotoninergic neurons in the 
DRN that expressed hM3Dq and were responsible for the increased sleep phenotype 
within the first hour following 9am CNO injection, we constructed a heatmap. To make 
the heatmap, the injection sites (hM3Dq-mCherry+ somata) for each mouse were drew 
onto a series of standard sections through the DRN and overlaid. The region of the DRN 
that most mice expressed viral transfection where labelled white. From this, we inferred 6 
out of 8 mice (2 mice were not included in analysis because there was no transfection 
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present) had transfected neurons in the DRN specifically between Bregma -4.48 and -
4.60, with some outliers more rostral or caudal but still within the DRN (Figure 13). 
 
Figure 13. Heatmap showing overlapping regions of transfected neurons in SERT-Cre mice. Series of 
standard sections from Bregma -4.36 to -4.72 (Paxinos and Franklin, 2001) illustrating the overlap between 
injection sites in SERT-Cre mice (n=6). 	
Conditional activation of serotoninergic DRN neurons does not reduce anxiety 
To further characterize the conditional activation of serotoninergic neurons in the 
DRN, we conducted a battery of anxiety-related behavioral tests that began with the open 
field test and ended with the elevated plus maze. All mice were pretreated with saline or 
CNO 10 min prior to challenge in the open field test and elevated plus maze in a 
randomized within-subject crossover design over two separate days, at least 48-hours 
apart to ensure CNO washout. Following CNO injection, mice transfected with hM3Dq 
did not significantly spend more time in the center compared to mice following saline 
injection and transfected with hM3Dq, and mice following CNO and saline injection that 
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were not transfected with hM3Dq (transfection factor F [1,12] =1.032, p=0.3298; 
injection factor F [1,12] =0.5673, p=0.4659). Additionally, there was no statistical 
significant difference in time spent in the open arm vs. the closed arm in mice following 
CNO injection transfected with hM3Dq compared to mice following saline injection that 
were transfected with hM3Dq, and mice following CNO and saline injection with no 
transfection of hM3Dq (transfection factor F [1,12] =0.1436, p=0.7113; injection factor F 
[1,12] =0.3731, p=0.5527) (Figure 14). Importantly, there was no difference between 
conditions on spontaneous locomotion (measured by distance travelled), or velocity in the 
open field (transfection factor F [1,12] =0.5117, p=0.4881; injection factor F [1,12] 
=0.1056, p=0.7508) as well as no difference in spontaneous locomotion, or velocity in the 
elevated plus maze (transfection factor F [1,12] =0.3884, p=0.5204; injection factor F 
[1,12] =0.0732, p=0.7914) (Figure 15) following CNO injection compared to saline 
injection, showing anxiety-related behavior in the open field or the elevated plus maze 
was not due to activation of a motor pathway. 
	
Figure 14. Anxiety-related behaviors following injection of CNO, saline. Mice with hM3Dq 
transfection (n=6) and without hM3Dq transfection (n=2) following CNO or saline injection in an open 
field test (left) and an elevated plus maze (right). Mean + SEM, two-way ANOVA. 
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Figure 15. Administration of CNO did not alter spontaneous locomotor activity during anxiety-
related behavioral tasks. Mice with hM3Dq transfection (n=6) and without hM3Dq transfection (n=2) 
were pretreated with CNO or saline and challenged in the open field test. These mice did not have 
differences in A) distance travelled or B) velocity. Similarly, the same mice when challenged in the 
elevated plus maze also did not have significant differences in C) distance travelled or D) velocity. Mean + 
SEM, two-way ANOVA. 
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DISCUSSION 
 
 In the present study, we used a conditional chemogenetic technique to investigate 
the effect of selective and acute activation of serotoninergic neurons in the DRN on 
sleep-wake regulation and anxiolytic behavior. We demonstrated that acute and selective 
activation of serotoninergic DRN cells 1) increases NREM sleep during the first post-
injection hour, and 2) produces a modest anxiolytic effect in anxiety-related behavioral 
tests. 
 Early studies have indicated that serotonin might be a sleep-promoting 
neurotransmitter (Brodie et al., 1955; Delorme et al., 1965; Jouvet et al., 1965; Delorme 
et al., 1966; Koella, 1969). However this hypothesis was subsequently challenged by a 
study reporting high electrical activity of serotoninergic neurons in the DR during 
wakefulness in cats (McGinty & Harper, 1976) and reports of 5-HT release during 
wakefulness in rats via in vivo voltammetry (Cespuglio et al., 1984), leading to the idea 
that 5-HT was associated with wakefulness. Additionally, measures of extracellular levels 
of 5-HT via microdialysis during different states of sleep and wakefulness further 
supported the role of serotoninergic neurons associated with arousal (Portas & McCarley, 
1994). 
 While the foregoing work suggested a role for serotonin in sleep-wake behavior, 
experiments in which neurons in the DRN could be directly and specifically modulated 
remained lacking. A study that specifically and extensively (~80%) ablated 
serotoninergic neurons in the DRN reported no significant effects on NREM, REM, or 
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total sleep in rats (Lu et al., 2006). However, it is possible that compensatory mechanisms 
may have masked the effects of chronic depletion of these cells.  
Consequently, acute and selective activation or inactivation approaches for 
manipulating the serotoninergic neuronal population in the DRN are required, e.g. 
chemogenetics. A study in which serotoninergic DRN neurons were optogenetically 
activated reported a significant increase in wakefulness and decrease in NREM sleep (Ito 
et al., 2013). While optogenetics is advantageous for probing the action of neurons on a 
fast time scale, this study was limited to one non-physiological stimulation frequency of 
20 Hz and the authors failed to specify what stage of sleep the animals were in when light 
stimulation occurred, potentially affecting their data. 
 In this study, we used a conditional chemogenetics approach to permit acute and 
selective activation of serotoninergic neurons in the DRN while simultaneously 
measuring sleep-wake activity. Activation of this neuronal population resulted in a 
significant reduction of wakefulness and elevation of NREM sleep during the first hour 
after 9am CNO injection as compared to saline injection. This short-lasting effect might 
be indicative of the pharmacokinetic properties of CNO, which has been shown to 
achieve peak plasma levels within 15 min and become undetectable after two hours 
(Guettier et al., 2009). 
Furthermore, in the first hour after the 9am injection of CNO, animals treated 
with CNO exhibited a significant reduction in latency to sleep compared saline controls. 
While CNO-induced bout counts and mean bout length are slightly elevated compared to 
saline, neither are statistically significant. As the mice in this study were first injected 
with saline and then CNO at both time points, it would be beneficial to future 
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experiments to reverse the order and see if the effect is still prevalent. It should also be 
noted that the effect of saline injection on wakefulness was highly variable within the 
first hour compared to the CNO injection. Even though animals were handled during the 
four-day habituation period, this suggests that variability in the stress response of the 
injection could be mitigated in future studies by habituating mice to chronic injections 
prior to the experiment. 
The CNO injection at 6pm did not significantly reduce wakefulness or increasing 
NREM sleep compared to saline injection. Since 6pm is a time of low sleep pressure, this 
suggests that activating serotoninergic neurons is insufficient to overcome the drive of 
wakefulness. Additionally, this could be indicative of an interaction between the 
serotoninergic systems and the circadian clock (Ciarleglio et al., 2011). For example, 
rhythmic release and receptor binding of serotonin in the rat brain has been reported 
(Wesemann & Weiner, 1990). 5-HT levels in the SCN have also been reported to peak 
during the active phase in nocturnal animals (Cuesta et al., 2009). The suprachiasmatic 
nucleus (SCN), or primary mammalian circadian clock, also receives direct 
serotoninergic innervation from the median raphe nucleus and indirect serotoninergic 
innervation rom the DRN. It turn, the SCN, via the dorsomedial hypothalamic nucleus 
(DMH), projects to the DRN (Deurveilher & Semba, 2005). Previous studies have also 
reported that 5-HT acts in the SCN to mediate clock-resetting of behavioral phase-
resetting stimuli (Dudley et al., 1998) and it is likely the that DRN serotonin output 
modulates non-photic phase resetting responses (Glass et al., 2003). Hence a complex 
and incompletely understood interaction between the circadian clock and the DRN 
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serotoninergic system may contribute to the apparent time of day dependent effects on 
sleep following CNO administration. 
 In addition, we report no significant difference in anxiety after acutely and 
selectively activating serotoninergic neurons in the DRN in the open field test and 
elevated plus maze. While we hypothesized that activating serotoninergic cells in the 
DRN would produce a similar effect to reported SSRIs, it is important to note that the 
effectiveness of SSRIs in treating anxiety derives more from clinical observations than 
animal models (Cryan & Sweeney, 2011). In fact, previous studies have reported few 
positive effects of SSRIs and moreover, anxiogenic effects are often observed in mice 
and rats (Sánchez & Meier, 1997; Borsini et al., 2002). Additionally, a recent study has 
shown that serotoninergic neurons in the DRN, via 5-HT2C receptors, enhance anxiety 
and activate an inhibitory subpopulation of corticotropin-releasing factor neurons in the 
bed nucleus of the stria terminalis (BNST), which silences anxiolytic BNST outputs to 
the VTA and LH. These results might explain previously reported acute SSRI-induced 
anxiogenic behaviors in rodents (Marcinkiewcz et al., 2016). 
Finally, the significant increase in NREM sleep post 9am injection of CNO 
compared to saline could also suggest that acutely and selectively activating 
serotoninergic DRN neurons dampens the stress effect caused by the injection. Previous 
work has shown a role for serotonin in coping mechanisms within the amygdala. For 
example, acute serotonin release directly activates GABAergic interneurons in the 
basolateral amygdala, via 5-HT2A receptors, and increases the frequency of inhibition in 
the rat (Rainnie, 1999). Additionally, serotoninergic fibers have been shown to 
preferentially target distinct populations of interneurons in the amygdala of the rat 
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(Muller et al., 2007). Therefore, it has been hypothesized that activation of DRN 
serotoninergic neurons would enhance inhibition in the basolateral amygdala and 
facilitate coping with a stressor (Lowry & Hale, 2010). To this end, activation 5-HT2A 
receptors in the basolateral amygdala was found to reduce fear and anxiety in guinea pigs 
(Leite-Panissi et al., 2006). 
 
Future Studies 
 To further investigate whether acutely and selectively activating DRN 
serotoninergic neurons promotes sleep, we intend to test the replicability and increase the 
power of the current study with the appropriate randomization and crossover design for 
CNO and saline administration in sleep-wake recordings and anxiety-related behavioral 
tests. Additionally, given the strong connection between the serotoninergic and circadian 
systems, we also intend to conduct a telemetry experiment to monitor acute temperature 
and activity of mice after CNO injection compared to saline to investigate whether time 
of day impacts CNO-induced effects. Finally, due to the apparent connection between 
DRN serotoninergic neurons and stress mediation, we could also measure the levels of 
cortisol, a stress hormone, after challenging CNO injected mice to stress.  
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